67367-33-3 Usage
General Description
4-Hydroxy-6-methylnicotinic acid is a chemical compound that falls under the category of pyridines and derivatives. Pyridines are compounds containing a pyridine ring, which is a six-membered aromatic ring with one nitrogen atom and five carbon atoms. Often found in plant and animal tissues, this compound has yet to have its comprehensive biological properties thoroughly studied, but it plays various roles in biochemistry. Being an organic compound, it has potential applications in organic synthesis and pharmaceutical applications. Its chemical formula is C7H7NO3 and its systematic name is 4-Hydroxy-6-methylpyridine-3-carboxylic acid.
Check Digit Verification of cas no
The CAS Registry Mumber 67367-33-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,3,6 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 67367-33:
(7*6)+(6*7)+(5*3)+(4*6)+(3*7)+(2*3)+(1*3)=153
153 % 10 = 3
So 67367-33-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H7NO3/c1-4-2-6(9)5(3-8-4)7(10)11/h2-3H,1H3,(H,8,9)(H,10,11)
67367-33-3Relevant articles and documents
A tautomeric ligand enables directed C-H hydroxylation with molecular oxygen
Li, Zhen,Wang, Zhen,Chekshin, Nikita,Qian, Shaoqun,Qiao, Jennifer X.,Cheng, Peter T.,Yeung, Kap-Sun,Ewing, William R.,Yu, Jin-Quan
, p. 1452 - 1457 (2021/06/30)
Hydroxylation of aryl carbon-hydrogen bonds with transition metal catalysts has proven challenging when oxygen is used as the oxidant. Here, we report a palladium complex bearing a bidentate pyridine/ pyridone ligand that efficiently catalyzes this reaction at ring positions adjacent to carboxylic acids. Infrared, x-ray, and computational analysis support a possible role of ligand tautomerization from monoanionic (L,X) to neutral (L,L) coordination in the catalytic cycle of aerobic carbon-hydrogen hydroxylation reaction. The conventional site selectivity dictated by heterocycles is overturned by this catalyst, thus allowing late-stage modification of compounds of pharmaceutical interest at previously inaccessible sites.